Showing 5321-5330 of 5956 results for "".
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovuhttps://modernod.com/news/novartis-responds-to-asrs-note-raising-safety-concerns-of-beovu/2477325/Novartis confirmed to Eyewire News that it is launching an internal and external review of new information that raises serious safety concerns over its wet age-related macular degeneration (AMD) drug Beovu (brolucizumab). On February 23, the American Society of Retinal Specialists (ASRS) s
- Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officerhttps://modernod.com/news/eyevance-pharmaceuticals-appoints-julie-speed-as-chief-commercial-officer/2477316/Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshk
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe
- Calvin Roberts, MD, Named President and CEO of Lighthouse Guildhttps://modernod.com/news/calvin-roberts-md-named-president-and-ceo-of-lighthouse-guild/2477286/Calvin Roberts, MD, has been elected President and CEO of Lighthouse Guild. Dr. Roberts will leave his position as Senior Vice President and Chief Medical Officer, Eye Care, at Bausch Health Companies, on March 31. Dr. Roberts i
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-additional-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2477282/Kodiak Sciences announced promising safety, efficacy, and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degener